Clinical Trial Update: REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure [Phase 2]

View source ↗

Summary

The study reports the completion of a Phase 2 trial evaluating REGN5381 in adults with heart failure and elevated pulmonary capillary wedge pressure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• REGN5381

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Heart Failure | Phase 2 | Status: COMPLETED